Werewolf Therapeutics (NASDAQ:HOWL) Price Target Cut to $7.00 by Analysts at Bank of America

Werewolf Therapeutics (NASDAQ:HOWL) had its price target cut by Bank of America from $8.00 to $7.00 in a research report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Other analysts have also recently issued reports about the stock. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities cut their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Werewolf Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $7.75.

Werewolf Therapeutics Trading Down 0.5%

Shares of NASDAQ:HOWL opened at $0.92 on Tuesday. The company has a market capitalization of $44.42 million, a PE ratio of -0.56 and a beta of 0.72. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics has a 12-month low of $0.60 and a 12-month high of $2.38. The business’s fifty day simple moving average is $1.56 and its 200-day simple moving average is $1.34.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, equities research analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Bioventures 2014 L.P. Mpm sold 140,488 shares of the company’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total value of $171,395.36. Following the transaction, the insider directly owned 6,007,122 shares of the company’s stock, valued at $7,328,688.84. This represents a 2.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Ansbert Gadicke sold 140,488 shares of the firm’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total value of $171,395.36. Following the completion of the transaction, the insider owned 6,007,122 shares of the company’s stock, valued at $7,328,688.84. This trade represents a 2.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,268,242 shares of company stock worth $4,162,838 in the last 90 days. 23.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HOWL. Susquehanna International Group LLP raised its position in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after buying an additional 13,439 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Werewolf Therapeutics during the third quarter worth $304,000. Vanguard Group Inc. lifted its position in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares during the period. Bridgeway Capital Management LLC boosted its holdings in Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after purchasing an additional 62,414 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.